MarketMoodz
Cramer Recommends Buying Becton Dickinson on Valuation
On June 3, 2026, CNBC Mad Money host Jim Cramer recommended buying Becton Dickinson (BDX) during the show’s lightning round, saying the stock is trading at the lowest level to the market he has ever seen. The quick bullish call could nudge short-term sentiment for the large-cap medtech name, but investors should treat it as a single data point within a broader strategy.
Key Takeaways
- Jim Cramer said on June 3, 2026: "I like Becton Dickinson. It is selling at the lowest level to the market that I have ever seen. I think you buy some."
- BDX was the focal stock in the lightning round and received a clear buy recommendation from Cramer.
- Other tickers discussed in the same segment included JFrog (FROG), MannKind (MNKD), Banco Santander (SAN) and BLZE, though some tickers in recaps can be misidentified.
- Cramer's lightning-round calls often move short-term sentiment and volume, so expect potential volatility and trading flows around BDX.
- Treat the recommendation as speculative — combine it with risk controls, diversification, and a structured entry/exit plan.
People Involved
- Jim CramerCNBC Mad Money host
Entities Involved
- Becton Dickinson (BDX)Focal stock; received a buy recommendation from Jim Cramer
- CNBC Mad MoneySource program of the lightning round
- JFrog (FROG)Ticker discussed during the segment
- MannKind (MNKD)Ticker discussed during the segment
- Banco Santander (SAN)Ticker discussed during the segment
- BLZETicker discussed during the segment (recap may misidentify tickers)
MarketMoodz Analysis
Cramer's buy call on Becton Dickinson is a short-form endorsement that can push retail interest and intraday volume toward BDX, particularly in options and small-cap-to-large-cap rotation flows. For investors, the practical impact is twofold: expect higher near-term volatility and possible analyst re-takes or price-target chatter, but don’t treat a lightning-round line as a replacement for earnings analysis, margin trends, or reimbursement dynamics that drive medtech stocks.
Historically, Cramer's lightning-round comments have produced quick price moves rather than sustained trend changes; a positive mention often triggers an immediate pop followed by mean reversion unless supported by fundamentals. BDX's long-term thesis — exposure to hospital consumables, diagnostic tools and an aging population — remains independent of pundit coverage, so evaluate valuation, cash flow, and upcoming catalysts (earnings, guidance, M&A chatter) before adding exposure.
What to watch next: monitor volume and options open interest after the segment, any analyst revisions following the mention, BDX’s next earnings or guidance updates, and potential clarification on tickers from the recap (the segment referenced JFrog/FROG, MNKD, SAN and BLZE). Keep position sizing disciplined and set clear entry and exit rules if you trade the headline-driven volatility.
Source: Original Article